(Q33371499)

English

Phase I dose escalation study of pegylated liposomal doxorubicin (Caelyx) in combination with topotecan in patients with advanced malignancies

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Phase I dose escalation study of pegylated liposomal doxorubicin (Caelyx) in combination with topotecan in patients with advanced malignancies (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

based on heuristic

inferred from title

Sandrine Faivre

object named as

Sandrine Faivre

2

0 references

author name string

Hervé Ghesquières

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Latifa Djafari

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Patricia Pautier

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Catherine Lhommé

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Stéphanie Lozahic

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Kamel Djazouli

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jean-Pierre Armand

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Eric Raymond

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

1 September 2006

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

24

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

413-421

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

https://scigraph.springernature.com/pub.10.1007/s10637-006-7520-2

0 references

Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-006-7520-2

21 January 2018

A phase I study of liposomal doxorubicin (Doxil) with topotecan

1 reference

https://api.crossref.org/works/10.1007%2FS10637-006-7520-2

21 January 2018

Synergistic interactions of combinations of topotecan with standard drugs in primary cultures of human tumor cells from patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/16763786

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

1 reference

https://pubmed.ncbi.nlm.nih.gov/16763786

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16763786

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16763786

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sequence effect of irinotecan (CPT-11) and topoisomerase II inhibitors in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/16763786

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs

1 reference

https://pubmed.ncbi.nlm.nih.gov/16763786

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin

1 reference

https://pubmed.ncbi.nlm.nih.gov/16763786

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16763786

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes

1 reference

https://pubmed.ncbi.nlm.nih.gov/16763786

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16763786

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel

1 reference

https://pubmed.ncbi.nlm.nih.gov/16763786

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I trial of escalating doses of topotecan in combination with a fixed dose of pegylated liposomal doxorubicin in women with müllerian malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/16763786

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes

1 reference

https://pubmed.ncbi.nlm.nih.gov/16763786

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies

1 reference

https://pubmed.ncbi.nlm.nih.gov/16763786

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The current status of camptothecin analogues as antitumor agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/16763786

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/16763786

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I study of topotecan followed sequentially by doxorubicin in patients with advanced malignancies.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16763786

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16763786

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Management of treatment-related toxicity in advanced ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16763786

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Topotecan increases topoisomerase IIalpha levels and sensitivity to treatment with etoposide in schedule-dependent process

1 reference

https://pubmed.ncbi.nlm.nih.gov/16763786

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Weekly topotecan: an alternative to topotecan's standard daily x 5 schedule?

1 reference

https://pubmed.ncbi.nlm.nih.gov/16763786

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Topotecan: a review of its efficacy in small cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16763786

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-006-7520-2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33371499&oldid=1536569848"